Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 1/2017

01-01-2017 | Review

Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review

Authors: Sepanta Hosseinpour, Fatemeh Mashhadiabbas, Mitra Ghazizadeh Ahsaie

Published in: Pathology & Oncology Research | Issue 1/2017

Login to get access

Abstract

Oral verrucous carcinoma (OVC), a low-grade variant of oral squamous cell carcinoma (OSCC), is most frequently seen in the oral cavity. No clear etiology has been found for this lesion, but human papilloma virus, chewing betel nuts, and ultraviolet radiation are suggested as probable causes. Differential diagnosis of OVC is challenging for oral pathologists. The aim of this study was to review the molecular-based approaches for differential diagnosis of OVC. An electronic search was conducted in Medline and Scopus from January 2004 to July 2015 limited to English language publications. Published papers on verrucous carcinoma (VC) were found according to the inclusion and exclusion criteria and analyzed qualitatively. Data extraction were performed according to PRISMA statement. A total of 423 articles were reviewed; out of which, 26 articles completely fulfilled the inclusion criteria. Most of the included studies investigated proliferative and apoptotic biomarkers such as p53 and Ki67. No definite conclusion was drawn for cytoskeletal biomarkers due to variability of factors and lack of significant expression. However, it seems that cytokeratin10 (CK 10) can be useful for differentiation of OVC and benign squamous lesions. Among cell surface and extracellular matrix biomarkers tissue biomarkers, matrix metalloproteinase (MMP)-2, −9, CD31 and CD68 seem to be useful for differentiation of OVC and OSCC and glucose transporter-1 (GLUT-1) can help in differentiation of OVC from oral epithelial dysplasia. Differences among OVC, OSCC and normal epithelium in expression profiles of the investigated biomarkers help in their differential diagnosis; although, clinicohistopathological similarities among verrucous hyperplasia, noninvasive OVC and invasive well-differentiated OSCC make the diagnosis difficult. Further studies are required to better differentiate these oral lesions.
Literature
1.
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046):1157–1160CrossRefPubMedPubMedCentral
2.
Ackerman LV (1948) Verrucous carcinoma of the oral cavity. Surgery 23(4):670–678PubMed
3.
Eversole L (2000) Papillary lesions of the oral cavity: relationship to human papillomaviruses. J Calif Dent Assoc 28(12):922–927PubMed
4.
Sharan RN, Mehrotra R, Choudhury Y, Asotra K (2012) Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One 7(8):e42759CrossRefPubMedPubMedCentral
5.
Johnson N (2001) Tobacco use and oral cancer: a global perspective. J Dent Educ 65(4):328–339PubMed
6.
Schmitt J, Seidler A, Diepgen T, Bauer A (2011) Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 164(2):291–307CrossRefPubMed
7.
Jacobson S, Shear M (1972) Verrucous carcinoma of the mouth. J Oral Pathol Med 1(2):66–75CrossRef
8.
Garcia NG, Oliveira DT, Hanemann JAC, Pereira AAC (2012) Oral verrucous carcinoma mimicking a chronic candidiasis: a case report. Case reports in oncological medicine 2012
9.
Koch BB, Trask DK, Hoffman HT, Karnell LH, Robinson RA, Zhen W, Menck HR (2001) National survey of head and neck verrucous carcinoma. Cancer 92(1):110–120CrossRefPubMed
10.
Yeh C-J (2003) Treatment of verrucous hyperplasia and verrucous carcinoma by shave excision and simple cryosurgery. Int J Oral Maxillofac Surg 32(3):280–283CrossRefPubMed
11.
Schrader M, Laberke H, Jahnke K (1987) Lymphatic metastases of verrucous carcinoma (Ackerman tumor). HNO 35(1):27–30PubMed
12.
Jiang L, Wang S, Chen X (2001) Immunohistochemical and ultrastructural study of basement membrane in oral verrucous carcinoma. Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi=. Chinese J Stomatol 36(4):308
13.
Barnes L (2005) Pathology and genetics of head and neck tumours, 9. IARC,
14.
15.
Neville BW (2009) Oral and maxillofacial pathology. Elsevier Brasil
16.
Kang C-J, Chang JT-C, Chen T-M, Chen I-H, Liao C-T (2003) Surgical treatment of oral verrucous carcinoma. choice 1:2
17.
McClure D, Gullane P, Slinger R, Wysocki G (1984) Verrucous carcinoma--changing concepts in management. J Otolaryngol 13(1):7–12PubMed
18.
Warshaw EM, Templeton S, Washington C (2000) Verrucous carcinoma occurring in a lesion of oral lichen planus. Cutis New York 65(4):219–222
19.
Rinker MH, Fenske NA, Scalf LA, Glass LF (2001) Histologic variants of squamous cell carcinoma of the skin. Cancer Control 8(4):354–363PubMed
20.
Lübbe J, Kormann A, Adams V, Hassam S, Grätz K, Panizzon R, Burg G (1996) HPV-11-and HPV-16-associated oral verrucous carcinoma. Dermatology 192(3):217–221CrossRefPubMed
21.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944CrossRefPubMed
22.
Thompson L (2006) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 85(2):74–74PubMed
23.
Gale N, Zidar N (2006) Benign and potentially malignant lesions of the squamous epithelium and squamous cell carcinoma. Springer
24.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefPubMed
25.
Angadi CV, Angadi VP (2015) GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma. J Oral Sci 57(2):115–122CrossRefPubMed
26.
Wang Y-H, Tian X, Liu O-S, Fang X-D, Quan H-Z, Xie S, Gao S, Tang Z-G (2014) Gene profiling analysis for patients with oral verrucous carcinoma and oral squamous cell carcinoma. Int J Clin Exp Med 7(7):1845PubMedPubMedCentral
27.
El-Rouby DH (2010) Association of macrophages with angiogenesis in oral verrucous and squamous cell carcinomas. J Oral Pathol Med 39(7):559–564CrossRefPubMed
28.
Gao H, Ho J, Lee H, Yu C (2009) The presence of Merkel cells and CD10-and CD34-positive stromal cells compared in benign and malignant oral tumors. Oral Dis 15(4):259–264CrossRefPubMed
29.
Paral KM, Taxy JB, Lingen MW (2014) CD34 and α smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 117(4):477–482CrossRefPubMed
30.
Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C (2010) Aberrant. BETA-catenin expression in the histologic differentiation of oral squamous cell carcinoma and verrucous carcinoma: an immunohistochemical study. J Oral Sci 52(4):633–640CrossRefPubMed
31.
Oliveira M, Silveira E, Godoy G, Amorim R, Costa A, Queiroz L (2005) Immunohistochemical evaluation of intermediate filament proteins in squamous papilloma and oral verrucous carcinoma. Oral Dis 11(5):288–292CrossRefPubMed
32.
Mohtasham N, Babakoohi S, Shiva A, Shadman A, Kamyab-Hesari K, Shakeri M, Sharifi-Sistani N (2013) Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol, Res Pract 209(2):110CrossRef
33.
Zargaran M, Eshghyar N, Vaziri PB, Mortazavi H (2011) Immunohistochemical evaluation of type IV collagen and laminin-332 γ2 chain expression in well-differentiated oral squamous cell carcinoma and oral verrucous carcinoma: a new recommended cut-off. J Oral Pathol Med 40(2):167–173CrossRefPubMed
34.
Arduino PG, Carrozzo M, Pagano M, Broccoletti R, Scully C, Gandolfo S (2010) Immunohistochemical expression of basement membrane proteins of verrucous carcinoma of the oral mucosa. Clin Oral Investig 14(3):297–302CrossRefPubMed
35.
Ray JG, Mukherjee S, Pattanayak S, Chaudhuri K (2011) Oral verrucous carcinoma–a misnomer? Immunohistochemistry based comparative study of two cases. BMJ Case Rep 2011. doi:10.​1136/​bcr.​11.​2010.​3479
36.
Nishikawa T, Hara R, Ito Y, Masuno K, Tominaga K, Wato M, Watanabe Y, Mori M, Tanaka A (2005) Aberrant expression patterns of histone H3 mRNA, p53, cyclin D1, and cyclin B1 in oral neoplastic epithelial lesions. Acta Histochem Cytochem 38(1):53–59CrossRef
37.
Tran TN, Liu Y, Takagi M, Yamaguchi A, Fujii H (2005) Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-associated oral carcinoma in a Vietnamese non-smoking/non-drinking female population. J Oral Pathol Med 34(3):150–156CrossRefPubMed
38.
Adegboyega PA, Boromound N, Freeman DH (2005) Diagnostic utility of cell cycle and apoptosis regulatory proteins in verrucous squamous carcinoma. Appl Immunohistochem Mol Morphol 13(2):171–177CrossRefPubMed
39.
Lin HP, Wang YP, Chiang CP (2011) Expression of p53, MDM2, p21, heat shock protein 70, and HPV 16/18 E6 proteins in oral verrucous carcinoma and oral verrucous hyperplasia. Head Neck 33(3):334–340PubMed
40.
Pentenero M, Donadini A, Di Nallo E, Maffei M, Marino R, Familiari U, Broccoletti R, Castagnola P, Gandolfo S, Giaretti W (2011) Distinctive chromosomal instability patterns in oral verrucous and squamous cell carcinomas detected by high-resolution DNA flow cytometry. Cancer 117(22):5052–5057CrossRefPubMed
41.
Wang Y, Tang Z, Zhao S, Xie X, Yao Z, Liu C, Qu B, Chen Y, Xiao Z, Li G (2013) Proteomic analysis of human oral verrucous carcinoma. Afr J Biotechnol 10(60):13004–13013
42.
Quan H, Tang Z, Zhao L, Wang Y, Liu O, Yao Z, Zuo J (2012) Expression of αB-crystallin and its potential anti-apoptotic role in oral verrucous carcinoma. Oncol Lett 3(2):330
43.
de Spíndula-Filho JV, da Cruz AD, Oton-Leite AF, Batista AC, Leles CR, Alencar RCG, Saddi VA, Mendonça EF (2011) Oral squamous cell carcinoma versus oral verrucous carcinoma: an approach to cellular proliferation and negative relation to human papillomavirus (HPV). Tumor Biol 32(2):409–416CrossRef
44.
45.
Zargaran M, Eshghyar N, Baghaei F, Moghimbeigi A (2012) Assessment of cellular proliferation in oral verrucous carcinoma and well-differentiated oral squamous cell carcinoma using Ki67: a non-reliable factor for differential diagnosis? Asian Pac J Can Prev: APJCP 13(11):5811CrossRef
46.
Terada T (2012) Squamous cell carcinoma arising within verrucous carcinoma of the oral cavity: a case report. Int J Clin Exp Pathol 5(4):363PubMedPubMedCentral
47.
Odar K, Boštjančič E, Gale N, Glavač D, Zidar N (2012) Differential expression of microRNAs miR-21, miR-31, miR-203, miR-125a-5p and miR-125b and proteins PTEN and p63 in verrucous carcinoma of the head and neck. Histopathology 61(2):257CrossRefPubMed
48.
Patil GB, Hallikeri KS, Balappanavar AY, Hongal SG, Sanjaya PR, Sagari SG (2013) Cyclin B1 overexpression in conventional oral squamous cell carcinoma and verrucous carcinoma-A correlation with clinicopathological features. Med Oral, Patol Oral Cir Bucal 18(4):e585CrossRef
49.
Mallick S, Breta M, Gupta SD, Dinda AK, Mohanty BK, Singh MK (2015) Angiogenesis, proliferative activity and dna ploidy in oral verrucous carcinoma: a comparative study including verrucous hyperplasia and squamous cell carcinoma. Pathol Oncol Res 21(4):1249–1257
50.
Samman M, Wood HM, Conway C, Stead L, Daly C, Chalkley R, Berri S, Senguven B, Ross L, Egan P (2015) A novel genomic signature reclassifies an oral cancer subtype. Int J Cancer 137(10):2364–2373CrossRefPubMed
51.
Klieb HBE, Raphael SJ (2007) Comparative study of the expression of p53, Ki67, E-cadherin and MMP-1 in verrucous hyperplasia and verrucous carcinoma of the oral cavity. Head and neck pathology 1(2):118–122CrossRefPubMedPubMedCentral
52.
Poh CF, Zhang L, Lam WL, Zhang X, An D, Chau C, Priddy R, Epstein J, Rosin MP (2001) A high frequency of allelic loss in oral verrucous lesions may explain malignant risk. Lab Investig 81(4):629–634CrossRefPubMed
53.
Ho P-S, Chen P-L, Warnakulasuriya S, Shieh T-Y, Chen Y-K, Huang I-Y (2009) Malignant transformation of oral potentially malignant disorders in males: a retrospective cohort study. BMC Cancer 9(1):260CrossRefPubMedPubMedCentral
54.
Barnes L, Eveson J, Reichart P, Sidransky D (2005) Oral cavity and oropharynx. World Health Organization Classification of tumors Pathology and genetics of Head and Neck tumors Lyon: International Agency for Research on Cancer Press:164–208
55.
Niparko J, Rubinstein M, McClatchey K (1988) Invasive squamous cell carcinoma within verrucous carcinoma. J Otolaryngol 17(1):38–40PubMed
56.
Rajendran R, Varghese I, Sugathan C (1988) Ackerman’s tumour (verrucous carcinoma) of the oral cavity: a clinico-epidemiologic study of 426 cases. Aust Dent J 33(4):295–298CrossRefPubMed
57.
Jyothirmayi R, Sankaranarayanan R, Varghese C, Jacob R, Nair MK (1997) Radiotherapy in the treatment of verrucous carcinoma of the oral cavity. Oral Oncol 33(2):124–128CrossRefPubMed
58.
59.
Yoshimura Y, Mishima K, Obara S, Nariai Y, Yoshimura H, Mikami T (2001) Treatment modalities for oral verrucous carcinomas and their outcomes: contribution of radiotherapy and chemotherapy. Int J Clin Oncol 6(4):192–200CrossRefPubMed
60.
Sturgeon C, Hammond E, Chang S, Sölétormos G, Hayes D (2006) NACB: practice guidelines and recommendations for use of tumor markers in the clinic: quality requirements [section 2] 2008. Draft Guidelines
61.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed
62.
Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456–1466CrossRefPubMed
63.
Kurman RJ, Norris HJ (1976) Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer 38(6):2404–2419CrossRefPubMed
64.
Cuperlovic-Culf M, Belacel N, Ouellette RJ (2005) Determination of tumour marker genes from gene expression data. Drug Discov Today 10(6):429–437CrossRefPubMed
65.
Copper D, Schermer A, Sun T (1985) Classification of human epithelia and their neoplasms using monoclonal antibodies to keratin: strategies, applications and limitations. Lab Investig 52:243–256CrossRef
66.
Gown A, Vogel A (1984) Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol 114(2):309PubMedPubMedCentral
67.
Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31:205–262PubMed
68.
Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810CrossRefPubMed
69.
Queimado L, Obeso D, Hatfield MD, Yang Y, Thompson DM, Reis AM (2008) Dysregulation of Wnt pathway components in human salivary gland tumors. Archives Otolaryngol–Head Neck Surg 134(1):94–101CrossRef
70.
Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp R, Rimm D, Psyrri A (2005) β-catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 11(7):2471–2477CrossRefPubMed
71.
Wilson DF, De-Jun J, Pierce AM, Wiebkin OW (1999) Oral cancer: role of the basement membrane in invasion. Aust Dent J 44(2):93–97CrossRefPubMed
72.
Souza LFP, Souza VF, Silva LDG, Santos JN, Reis SRA (2007) Expression of basement membrane laminin in oral squamous cell carcinomas. Rev Bras Otorrinolaringol 73(6):768–774CrossRef
73.
Pinto GA, Vassallo J, Andrade LALDA, Magna LA (1998) Immunohistochemical study of basement membrane collagen IV in uterine cervix carcinoma. Sao Paulo Medical Journal 116(6):1846–1851CrossRefPubMed
74.
Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG, Soares FA (2011) GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics 66(6):965–972CrossRefPubMedPubMedCentral
75.
Barth PJ, Zu Schweinsberg TS, Ramaswamy A, Moll R (2004) CD34+ fibrocytes, α-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch 444(3):231–234CrossRefPubMed
76.
Ramaswamy A, Moll R, Barth PJ (2003) CD34+ fibrocytes in tubular carcinomas and radial scars of the breast. Virchows Arch 443(4):536–540CrossRefPubMed
77.
Erdag G, Qureshi HS, Patterson JW, Wick MR (2008) CD34-positive dendritic cells disappear from scars but are increased in pericicatricial tissue. J Cutan Pathol 35(8):752–756CrossRefPubMed
78.
Barth PJ, Moll R, Ramaswamy A (2005) Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch 446(5):532–536CrossRefPubMed
79.
Betz P, Nerlich A, Wilske J, Tübel J, Wiest I, Penning R, Eisenmengen W (1992) Time-dependent pericellular expression of collagen type IV, laminin, and heparan sulfate proteoglycan in myofibroblasts. Int J Legal Med 105(3):169–172CrossRefPubMed
80.
Cotran RS, Kumar V, Collins T, Robbins SL (1999) Robbins pathologic basis of disease.62–63, 82, 206–209, 302–303, 328–331
81.
Mohtasham N, Babakoohi S, Shiva A, Shadman A, Kamyab-Hesari K, Shakeri M-T, Sharifi-Sistani N (2013) Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Prac 209(2):110–114CrossRef
82.
Cardon-Cardo C (1995) Mutations of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 147:545–560
83.
Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K (2002) Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 8(3):817–822PubMed
84.
Saito T, Nakajima T, Mogi K (1999) Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas. J Oral Pathol Med 28(5):226–232CrossRefPubMed
85.
Todd R, Hinds P, Munger K, Rustgi A, Opitz O, Suliman Y, Wong D (2002) Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 13(1):51–61CrossRefPubMed
86.
Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835):342–348CrossRefPubMed
87.
Macluskey M, Chandrachud LM, Pazouki S, Green M, Chisholm DM, Ogden GR, Schor SL, Schor AM (2000) Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression. J Pathol 191(4):368–375CrossRefPubMed
88.
Rousseau A, Lim M, Lin Z, Jordan R (2001) Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol 37(3):268–275CrossRefPubMed
89.
Yuan Y, Zeng Z-Y, Liu X-H, Gong D-J, Tao J, Cheng H-Z, Huang S-D (2011) MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer 11(1):57CrossRefPubMedPubMedCentral
90.
Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R (2011) Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res 17(16):5287–5298CrossRefPubMed
91.
Furuta M, Kozaki K-I, Tanaka S, Arii S, Imoto I, Inazawa J (2009) miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31:766–776
92.
Bueno MJ, de Castro IP, de Cedrón MG, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernández-Piqueras J, Malumbres M (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13(6):496–506CrossRefPubMed
93.
Lena A, Shalom-Feuerstein R, di Val Cervo PR, Aberdam D, Knight R, Melino G, Candi E (2008) miR-203 represses’ stemness’ by repressing Np63. Cell Death Differ 15(7):1187CrossRefPubMed
Metadata
Title
Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review
Authors
Sepanta Hosseinpour
Fatemeh Mashhadiabbas
Mitra Ghazizadeh Ahsaie
Publication date
01-01-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0150-x

Other articles of this Issue 1/2017

Pathology & Oncology Research 1/2017 Go to the issue

Original Article

Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma

Original Article

Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability

Original Article

Effects of Mesalazine on Morphological and Functional Changes in the Indomethacin-Induced Inflammatory Bowel Disease (Rat Model of Crohn’s Disease)

Original Article

Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients

Original Article

Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer

Original Article

Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits